ValuEngine upgraded shares of Teladoc (NYSE:TDOC) from a sell rating to a hold rating in a research report released on Friday, February 2nd.
A number of other equities research analysts have also issued reports on the company. Canaccord Genuity raised their price target on Teladoc from $42.00 to $43.00 and gave the stock a buy rating in a research note on Wednesday, January 31st. Jefferies Group began coverage on Teladoc in a research note on Friday, January 26th. They set a buy rating and a $40.00 price target for the company. KeyCorp reissued a buy rating and set a $41.00 price target on shares of Teladoc in a research note on Wednesday, January 10th. Citigroup began coverage on Teladoc in a research note on Thursday, January 4th. They set a buy rating for the company. Finally, Deutsche Bank began coverage on Teladoc in a research note on Friday, December 8th. They set a buy rating and a $39.00 price target for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. Teladoc presently has an average rating of Buy and an average target price of $39.43.
Shares of Teladoc (TDOC) traded down $0.10 during mid-day trading on Friday, hitting $32.95. The company had a trading volume of 1,092,266 shares, compared to its average volume of 1,163,216. Teladoc has a 52-week low of $19.60 and a 52-week high of $38.40. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08. The company has a market cap of $1,879.76, a price-to-earnings ratio of -22.88 and a beta of 0.49.
In other Teladoc news, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the transaction, the chief executive officer now directly owns 718,261 shares in the company, valued at approximately $23,695,430.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Hirschhorn sold 30,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $989,700.00. Following the transaction, the chief financial officer now owns 5,203 shares in the company, valued at $171,646.97. The disclosure for this sale can be found here. Company insiders own 4.47% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Raymond James Trust N.A. increased its holdings in shares of Teladoc by 36.2% in the 3rd quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock valued at $330,000 after acquiring an additional 2,643 shares during the period. American International Group Inc. increased its holdings in shares of Teladoc by 8.1% in the 3rd quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock valued at $1,196,000 after acquiring an additional 2,697 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after acquiring an additional 2,707 shares during the period. Emerald Advisers Inc. PA increased its holdings in shares of Teladoc by 0.5% in the 4th quarter. Emerald Advisers Inc. PA now owns 566,096 shares of the health services provider’s stock valued at $19,728,000 after acquiring an additional 2,784 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Teladoc in the 4th quarter valued at $101,000.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/11/valuengine-upgrades-teladoc-tdoc-to-hold.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.